126 related articles for article (PubMed ID: 38579266)
1. Targeting Breast Cancer Using 177 Lu-Labeled Trastuzumab and Trastuzumab Fragment : First-in-Human Clinical Experience.
Rathore Y; Lakhanpal T; Chakraborty S; Chakravarty R; Mittal BR; Irrinki RNS; Laroiya I; Kaur K; Shukla J
Clin Nucl Med; 2024 Jun; 49(6):e258-e265. PubMed ID: 38579266
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist
Mitran B; Rinne SS; Konijnenberg MW; Maina T; Nock BA; Altai M; Vorobyeva A; Larhed M; Tolmachev V; de Jong M; Rosenström U; Orlova A
Int J Cancer; 2019 Dec; 145(12):3347-3358. PubMed ID: 31077356
[TBL] [Abstract][Full Text] [Related]
3. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
[TBL] [Abstract][Full Text] [Related]
4. Development 68Ga trastuzumab Fab and bioevaluation by PET imaging in HER2/neu expressing breast cancer patients.
Rathore Y; Shukla J; Laroiya I; Deep A; Lakhanpal T; Kumar R; Singh H; Bal A; Singh G; Gopal Thakur K; Mittal BR
Nucl Med Commun; 2022 Apr; 43(4):458-467. PubMed ID: 35131966
[TBL] [Abstract][Full Text] [Related]
5. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
6. MANOTA: a promising bifunctional chelating agent for copper-64 immunoPET.
Moreau M; Poty S; Vrigneaud JM; Walker P; Guillemin M; Raguin O; Oudot A; Bernhard C; Goze C; Boschetti F; Collin B; Brunotte F; Denat F
Dalton Trans; 2017 Oct; 46(42):14659-14668. PubMed ID: 28861553
[TBL] [Abstract][Full Text] [Related]
7. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes.
Moreau M; Raguin O; Vrigneaud JM; Collin B; Bernhard C; Tizon X; Boschetti F; Duchamp O; Brunotte F; Denat F
Bioconjug Chem; 2012 Jun; 23(6):1181-8. PubMed ID: 22519915
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent cell cycle arrest and apoptosis in HER2 breast cancer cells by
Sharma R; Kameswaran M; Pandey U; Dash A
J Cancer Res Ther; 2020; 16(6):1426-1434. PubMed ID: 33342808
[TBL] [Abstract][Full Text] [Related]
9. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
10. A kit to prepare (111)In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer.
Scollard DA; Chan C; Holloway CM; Reilly RM
Nucl Med Biol; 2011 Jan; 38(1):129-36. PubMed ID: 21220136
[TBL] [Abstract][Full Text] [Related]
11. Preparation of
Kameswaran M; Pandey U; Gamre N; Sarma HD; Dash A
Appl Radiat Isot; 2019 Jun; 148():184-190. PubMed ID: 30974402
[TBL] [Abstract][Full Text] [Related]
12. Clinical Internal Dosimetry and Biodistribution of 177 Lu-DOTA-Trastuzumab in HER2-Positive Metastatic and Locally Advanced Breast Carcinoma.
Narwadkar YS; Parghane RV; Sahu S; Lad S; Deep K; Wanage G; Suralkar T; Banerjee S; Gupta S; Basu S; Badwe RA
Clin Nucl Med; 2024 Apr; 49(4):e149-e155. PubMed ID: 38350067
[TBL] [Abstract][Full Text] [Related]
13. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
15. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
[TBL] [Abstract][Full Text] [Related]
16. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Bal C
Pharmaceuticals (Basel); 2021 Nov; 14(12):. PubMed ID: 34959613
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of
Sharma R; Mukherjee A; Kumar A; Sarma HD
Cancer Biother Radiopharm; 2024 Feb; 39(1):64-74. PubMed ID: 38363819
[No Abstract] [Full Text] [Related]
18. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
[TBL] [Abstract][Full Text] [Related]
19. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
